GENETIC TECHNOLOGIES LIMITED — Board/Management Information 2011

Oct 2, 2011

==> picture [595 x 69] intentionally omitted <==

==> picture [595 x 69] intentionally omitted <==

ASX ANNOUNCEMENT October 3[rd] , 2011

---

Appointment of Dr. Mervyn Cass as Company Director

The Board of Directors of Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) has with great pleasure appointed Dr. Mervyn Cass as a non-executive Director of the Company. An ASX Appendix 3X for Dr. Cass is attached to this announcement.

Dr. Cass is a practising medical practitioner and, after 28 years as the senior partner in an occupational medical practice in Port Melbourne, accepted the appointment as Medical Director of a plastic surgery centre in 1996. He was the founding Chairman of the Australasian Occupational Medical Group and was a Director of Wolfe Research Pty. Ltd., a private medial biotech company associated with RMIT University. He has been an advisor to the Victorian Government on Workers’ Compensation and Radiological Standards in general practice. Dr. Cass is currently an executive member of the Jewish Community Council of Victoria, the roof body of the Victorian Jewish Community.

The Company’s Chairman Mr. Sid Hack said, “The Directors of Genetic Technologies are delighted that Mervyn has agreed to join the Board. His substantial experience in the fields of medicine, women’s health and restorative surgery will be of great practical and immediate value in the growth and development of the Company’s cancer diagnostics business. We very much look forward to working with Mervyn at this important time in the history of the Company.”

---

FOR FURTHER INFORMATION PLEASE CONTACT

Dr. Paul D.R. MacLeman Chief Executive Officer Genetic Technologies Limited Phone: +61 3 8412 7000

Genetic Technologies Limited ABN 17 009 212 328 • Website : www.gtglabs.com • Email : info@gtglabs.com Registered Office • 60-66 Hanover Street Fitzroy Victoria 3065 Australia • Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia Phone +61 3 8412 7000 • Fax +61 3 8412 7040

Appendix 3X Initial Director’s Interest Notice

Rule 3.19A.1

Appendix 3X

Initial Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity	Genetic Technologies Limited
A.B.N.	17 009 212 328

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr. Mervyn Cass
Date of appointment	30 September 2011

Part 1 - Director’s relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Number & class of securities

None

• See chapter 19 for defined terms.

Appendix 3X Page 1

11/3/2002

Appendix 3X Initial Director’s Interest Notice

Part 2 – Director’s relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

	Name of holder & nature of interestNote: Provide details of the circumstances giving rise to therelevant interest.Cassen Nominees Pty. Ltd.<Cass Family Super Fund A/C>Member / Beneficiary	Number & class of Securities473,667 fully paid ordinary shares

Part 3 – Director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Not applicable Nature of interest Name of registered holder (if issued securities) No. and class of securities to which interest relates

Dated: 3 October 2011

• See chapter 19 for defined terms.

Appendix 3X Page 2

11/3/2002